Loading clinical trials...
Loading clinical trials...
A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome
Conditions
Interventions
TEV-50717
Placebo
Locations
56
United States
Teva Investigational Site 060-0160
Gainesville, Florida, United States
Teva Investigational Site 060-0166
Gulf Breeze, Florida, United States
Teva Investigational Site 060-0161
Miami, Florida, United States
Teva Investigational Site 060-0151
Orlando, Florida, United States
Teva Investigational Site 060-0153
Orlando, Florida, United States
Teva Investigational Site 060-0168
Atlanta, Georgia, United States
Start Date
May 31, 2018
Primary Completion Date
December 9, 2019
Completion Date
December 9, 2019
Last Updated
November 9, 2021
NCT06678737
NCT03851484
NCT04449068
NCT05558566
NCT06194305
NCT06873841
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions